Screening Process TRIZ Cases

Guide RNA arrays steer base editors to specific loci, enabling dense plant mutagenesis without double-strand breaks or major off-target effects.

Chemically modified C9orf72 siRNA improves selective CNS gene silencing for ALS and FTD while addressing delivery and off-target constraints.

Sequence-specific siRNA silences CD33 mRNA to lower Siglec3 levels and modulate neuroinflammation in CNS-targeted treatment.

Lipophilic dsRNA conjugates improve RNAi stability and cellular uptake to silence TMPRSS2 and reduce coronavirus entry and replication.

Targeted 2′-F oligonucleotides recruit ADAR enzymes for selective RNA editing, improving precision, stability, and pathogenic SNP correction.

Synthetic microRNAs modify host-cell gene expression to increase rAAV yield, genome titre, capsid titre, and potency.

Specific dsRNA agents silence ABLIM3 expression to address limited treatment efficacy in PTSD and age-related memory loss.

Conventional oligonucleotides lack sufficient potency; branched PRNP-targeting sequences inhibit mRNA by 50% to 80%.

Curing gRNAs remove prior editing vectors, reducing interference and enabling repeated genomic edits with high efficiency.

A pH-tuned SELEX process selects high-affinity aptamers for fibrinogen purification with mild, selective elution.

Oligonucleotides induce specific cytokine profiles through stable tertiary structures like G-quadruplexes.

RNA interference agents inhibit MUC5B mRNA to reduce excessive mucus production and slow pulmonary fibrosis progression.

Multi-type nucleic acid screening identifies accessible RNA regions, reducing off-target effects in silencing applications.

Helicase SELEX selects functional aptamers through enzymatic activity modulation, avoiding rigid structures from traditional immobilization.

Optimizing Gibbs free energy during aptamer conversion enables reliable surface tethering without costly screening campaigns.

Aptamers bind N-terminal amino acids and convert them into DNA sequences via visual signals.

Synthetic antisense oligonucleotides bind human CTGF mRNA to inhibit gene expression.

Replacing complex off-site instrumentation with an in-situ biosensor using synthetic RNA aptamers eliminates transport delays and reduces device complexity.

Segmented double-stranded RNA molecules bind C5 mRNA to lower protein levels, offering complementary treatment options beyond eculizumab.

Aptamer-fluorophore complexes enhance fluorescence signals through specific nucleic acid binding interactions.

SensAI assay evaluates RNAi triggers via altered machinery to identify potent molecules, reducing dosage costs and off-target effects.

Introducing a heterologous RNAi target site allows reversible gene suppression while minimizing off-target effects through tetracycline-inducible control.

Genome editing modifies CD34+ progenitor cells to boost fetal hemoglobin, addressing side effects of current sickle cell treatments.

Multiplexed SELEX generates aptamers to detect levamisole and cocaine simultaneously, resolving specificity and efficiency trade-offs.

AGE-SELEX incorporates bioactivity-guided selection rounds to resolve low resolution and unspecific elution in standard SELEX aptamer identification.

Segmented aptamers nested in variable loops preserve translational activity while enabling sensitive monitoring of cellular stress and disease states.

Double-stranded RNA oligonucleotides inhibit HTT-1A gene expression to counteract neurodegenerative effects of the pathogenic huntingtin variant.

Single-stranded antisense compounds target enhancer RNAs to inhibit TNFSF10 gene expression in human cells.

Specific nucleic acid aptamers bind STAT5 protein to inhibit cancer cell growth while reducing side effects from non-specific chemotherapy.

A hybrid nucleic acid molecule combines a Cyclin D1 reporter region with a genetically modified target sequence to enable precise siRNA screening.

Engineered aptamers maintain binding affinity against viral mutations, enabling accurate subtype identification in diagnostic kits.

Split-pool synthesis on beads incorporates monothioate backbone substitutions to enhance nuclease resistance without disrupting binding affinity.

Aptamers bind selectively to LDL particles, replacing complex NMR instrumentation with cost-effective point-of-care testing.

A riboswitch system with a tryptophan aptamer and selectable marker gene enables rapid screening of high-producing microorganisms.